Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Eupraxia Pharmaceuticals Inc. (EPRX : NSDQ)

• Company Description    Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC. Number of Employees: 49

• Price / Volume Information    Yesterday's Closing Price: $7.10 Daily Weekly Monthly 20 Day Moving Average: 197,240 shares Shares Outstanding: 60.43 (millions) Market Capitalization: $429.08 (millions) Beta: 1.19 52 Week High: $9.32 52 Week Low: $3.67 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.07% -6.85% 12 Week -13.20% -19.76% Year To Date -5.96% -15.49%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201-2067 CADBORO BAY RD. - VICTORIA,A1 V8R 5G4 CAN ph: 250-590-3968 fax: - investors@eupraxiapharma.com http://www.eupraxiapharma.com/home/default.aspx

• General Corporate Information    Officers James A. Helliwell - Chief Executive Officer Simon Pimstone - Chairman Alex Rothwell - Chief Financial Officer and President Richard M. Glickman - Director John Montalbano - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29842P105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 60.43 Most Recent Split Date: (:1) Beta: 1.19 Market Capitalization: $429.08 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.85 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.03 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -9.52% vs. Previous Quarter: 37.84% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -87.56 12/31/25 - -167.68 09/30/25 - -283.52 ROA 03/31/26 - -51.20 12/31/25 - -66.72 09/30/25 - -65.28 Current Ratio 03/31/26 - 19.31 12/31/25 - 15.12 09/30/25 - 23.98 Quick Ratio 03/31/26 - 19.31 12/31/25 - 15.12 09/30/25 - 23.98 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 1.76 12/31/25 - 1.41 09/30/25 - 1.58 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.02 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 1.31 12/31/25 - 0.09 09/30/25 - 0.11

Powered by Zacks Investment Research ©